Abstract:Background: It has been reported that PKC theta plays an important role in the immune response by regulating the cellular activity of T cells and, thus, the production of immune factors such as IL-2.PKC theta protein is mainly expressed in T lymphocytes but not much in other cells and has a very good specificity. Therefore, it is very meaningful to use PKC theta protein as a novel target for immunosuppression. PKC theta is a valuable target that can be used to develop meaningful novel selective immunosuppressive agents. Methods: In this study, we constructed a 3-characteristic pharmacophoreRHAand used it to perform a virtual screening of the database. Then, we performed a molecular docking analysis of the compounds that scored high. The top five compounds with molecular docking scores were used as lead compounds, and structure-based ligand design via fragment substitution was applied to them, resulting in 20077 new compounds. We performed molecular docking analysis, binding free energy calculations, molecular dynamics simulation, and ADMET prediction on these new compounds and finally identified two compounds as new PKC theta inhibitors. Results and Discussions: Through the screening of pharmacophore, molecular design based on fragment substitution, molecular docking, we finally obtained two small molecules with higher scores than the positive control, in which the molecular docking score of P01 was -53.88 kcal/mol, and the molecular docking score of P02 was -51.20 kcal/mol, and then we performed the molecular dynamics simulation, free energy of binding calculations, and the prediction of ADMET properties for the compounds. The results showed that the ligands could form more stable complexes with the proteins, the binding free energy calculations of the ligand molecules were better than the positive control, all of them had good ADMET properties, and the compounds all had good drug similarity. Conclusion: Our results provided 2 new ligands that could serve as lead compounds for new PKC theta inhibitors in the future.

Exploring the prominent performance of CX-4945 derivatives as protein kinase CK2 inhibitors by a combined computational study.

Structural Determinants Of Cx-4945 Derivatives As Protein Kinase Ck2 Inhibitors: A Computational Study

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Exploring The Pivotal Role Of The Ck2 Hinge Region Sub-Pocket In Binding With Tricyclic Quinolone Analogues By Computational Analysis

Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking

Small Molecule Modulators Targeting Protein Kinase CK1 and CK2

Molecular Mechanism Concerning Conformational Changes of CDK2 Mediated by Binding of Inhibitors Using Molecular Dynamics Simulations and Principal Component Analysis

Effect of Substituents in Different Positions of Aminothiazole Hinge-Binding Scaffolds on Inhibitor–CDK2 Association Probed by Interaction Entropy Method

Structure-based Discovery of Novel CK2α-Binding Cyclic Peptides with Anti-cancer Activity.

Pharmacophore development, drug-likeness analysis, molecular docking, and molecular dynamics simulations for identification of new CK2 inhibitors

Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects

Computational Analysis for Residue-Specific CDK2-Inhibitor Bindings

Decoding molecular mechanism of inhibitor bindings to CDK2 using molecular dynamics simulations and binding free energy calculations

Insights Into The Impact Of Linker Flexibility And Fragment Ionization On The Design Of Ck2 Allosteric Inhibitors: Comparative Molecular Dynamics Simulation Studies

Discovery and Design of Tricyclic Scaffolds as Protein Kinase CK2 (CK2) Inhibitors through a Combination of Shape-Based Virtual Screening and Structure-Based Molecular Modification.

Molecular modelling on small molecular CDK2 inhibitors: an integrated approach using a combination of molecular docking, 3D-QSAR and pharmacophore modelling.

Discovery of Novel CK2 Leads by Cross-Docking Based Virtual Screening.

Exploring New Potential Pkcθ Inhibitors Using Pharmacophore Modeling, Molecular Docking Analysis, and Molecular Dynamics Simulations

Molecular Principle of the Cyclin-Dependent Kinase Selectivity of 4-(Thiazol-5-yl)-2-(phenylamino) Pyrimidine-5-carbonitrile Derivatives Revealed by Molecular Modeling Studies.

Using 3D-QSAR and Molecular Docking Insight into Inhibitors Binding with Complex-Associated Kinases CDK8